Contributions of Latin American researchers in the understanding the novel coronavirus outbreak: A literature review

Karen Y Fiesco-Sepúlveda Equal first author, 1, Luis Miguel Serrano-Bermúdez Coresp. Equal first author, 2

1 Epidemiology Program, Faculty of Health Sciences, Universidad Surcolombiana, Neiva, Colombia
2 Bioprocesses and Bioprospecting Group, Universidad Nacional de Colombia, Bogotá D.C., Colombia

Corresponding Author: Luis Miguel Serrano-Bermúdez
Email address: lmserranob@unal.edu.co

This paper aimed to give the visibility of Latin American researchers’ contributions to the comprehension of COVID-19; our method was a literature review. Currently, the world is facing a health and socioeconomic crisis caused by the novel coronavirus, SARS-CoV-2, and its disease COVID-19. Therefore, in less than four months, researchers have published a significant number of articles related to this novel virus. For instance, a search focused on the Scopus database on April 10, 2020, showed 1224 documents published by authors with 1797 affiliations from 80 countries. 25.4%, 24.0%, and 12.6% of these national affiliations were from China, Europe, and the USA, respectively, making these regions leaders in COVID-19 research. In the case of Latin America, on April 10, 2020, we searched different databases, such as Scopus, PubMed, and Web of Science, finding that the contribution of this region was 2.7±0.6% of the total publications found. In other words, we found 153 publications related to COVID-19 with at least one Latin American researcher. We summarized and processed the information from these 153 publications, finding active participation in topics like medical, social, and environmental considerations, bioinformatics, and epidemiology.
Contributions of Latin American researchers in the understanding the novel coronavirus outbreak: A literature review

Karen Y Fiesco-Sepúlveda1, Luis Miguel Serrano-Bermúdez2

1 Epidemiology Program, Faculty of Health Sciences, Universidad Surcolombiana, Neiva, Colombia.

2 Bioprocesses and Bioprospecting Group, Universidad Nacional de Colombia, Bogotá D.C., Colombia.

Corresponding Author:

Luis Miguel Serrano-Bermúdez

Carrera 30 No. 45-03, Bogotá D.C., 11001, Colombia

Email address: lmserranob@unal.edu.co (LMSB)
Abstract

This paper aimed to give the visibility of Latin American researchers’ contributions to the comprehension of COVID-19; our method was a literature review. Currently, the world is facing a health and socioeconomic crisis caused by the novel coronavirus, SARS-CoV-2, and its disease COVID-19. Therefore, in less than four months, researchers have published a significant number of articles related to this novel virus. For instance, a search focused on the Scopus database on April 10, 2020, showed 1224 documents published by authors with 1797 affiliations from 80 countries. 25.4%, 24.0%, and 12.6% of these national affiliations were from China, Europe, and the USA, respectively, making these regions leaders in COVID-19 research. In the case of Latin America, on April 10, 2020, we searched different databases, such as Scopus, PubMed, and Web of Science, finding that the contribution of this region was 2.7±0.6% of the total publications found. In other words, we found 153 publications related to COVID-19 with at least one Latin American researcher. We summarized and processed the information from these 153 publications, finding active participation in topics like medical, social, and environmental considerations, bioinformatics, and epidemiology.

1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel virus that mainly affects the respiratory system through the new coronavirus disease 2019 (COVID-19) (Ciotti et al., 2020). COVID-19 has spread quickly; thus, on March 11, 2020, the World Health Organization (WHO) declared it as a pandemic (Hussain et al., 2020). Since the first cases reported in Wuhan, China, in December 2019, until April 20, 2020, SARS-CoV-2 has affected
most countries in the world, with nearly 2.5 million people infected and 170,000 deaths (Johns
Hopkins University, 2020). Latin America is no stranger to this reality, totaling approximately
100,000 cases and 5,500 deaths, as shown in Table 1 (Johns Hopkins University, 2020).

However, these data may be lower than actual numbers because the number of tests per million
inhabitants remains low, which is caused by factors such as the limited availability of tests and
the difficulty of monitoring people without facilities like indigenous populations, vulnerable
groups, and Venezuelan refugees (Oliveira et al., 2020; Torres & Sacoto, 2020).

SARS-CoV-2, as SARS and MERS, belongs to the family Coronaviridae, has a zoonotic origin,
and can remain on some surfaces for considerable periods (Ciotti et al., 2020; van Doremalen et
al., 2020). Additionally, COVID-19 is a new disease with no yet vaccines or targeted drugs,
making the containment of the outbreak difficult (Carnero Contentti & Correa, 2020). Therefore,
the recommendation is the self-isolation to reduce COVID-19 spreading, especially in more
susceptible people as older adults or patients with comorbidities (Diaz-Quijano et al., 2020).

More general aspects of the current outbreak have been published in review articles according to
available information in the moment of publication. These reviews include other zoonotic
diseases (such as SARS and MERS), outbreak chronology, virus characteristics, zoonotic links,
transmission, diagnosis, disease characteristics, therapeutics & treatments, prevention,
epidemiological surveillance, and control (Ciotti et al., 2020; Cupertino et al., 2020; Huang et
al., 2020; Millán-Oñate et al., 2020; Palacios Cruz et al., 2020; Rodriguez-Morales et al., 2020a;
Sifuentes-Rodriguez & Palacios-Reyes, 2020; Siordia, 2020; Wu et al., 2020; Zhu et al., 2020).

In the past, during SARS and MERS outbreaks, research focused on coronaviruses increased
significantly, which was led by researchers from China and the USA (Bonilla-Aldana et al.,
2020b). This new outbreak is not an exception because thousands of articles have been published
in less than four months, where China, Europe, and the USA are leaders in the number of publications. In the case of Latin America, it is a region with an increasingly high contribution to science; thus, our question was, what are the contributions of Latin American researchers in understanding this novel coronavirus outbreak? Therefore, our purpose in this review was to highlight the contributions of this region in the comprehension of SARS-CoV-2 and COVID-19. The literature survey consisted of revising and summarizing publications with Latin American researchers. Keeping in mind that several researchers from this region work together with researchers from other continents, we included publications submitted by these types of international research groups. Hence, the relevance of this review focused on finding the research interests of Latin American researchers according to global and regional priorities.

2. Survey methodology

2.1. Search strategy

We performed the present review following the PRISMA guidelines. The search was done on April 10, 2020, using Scopus, Web of Science, PubMed, ScienceDirect, Wiley, Sage, LILACS, and SciELO databases because they are the main academic literature collections globally and regionally. Other databases like Springer Link were excluded because they do not allow to filtrate by affiliation. The search equation used had ("COVID 19" OR "COVID-19" OR "SARS-CoV-2" OR "SARS CoV 2" OR "SARS-CoV 2" OR "2019-nCoV" OR "2019 nCoV" OR "nCoV-2019" OR "nCoV 2019" OR "hCoV-19" OR "hCoV 19") in all fields and (Argentina OR Bolivia OR Brasil OR Brazil OR Chile OR Colombia OR Cuba OR Ecuador OR Salvador OR Guatemala OR Haiti OR Honduras OR Mexico OR Nicaragua OR Panama OR Paraguay OR
2.2. Article selection and data extraction

After the search stage, both reviewers (KYFS and LMSB) removed all duplicated publications, which included a manual revision because some publications were simultaneously in English, Spanish, or Portuguese. Later, we performed a second manual revision to verify that all publications had at least one researcher with a Latin American affiliation. After these two manual revisions, we did not exclude more publications, and final publications were included in the qualitative synthesis. Before the qualitative synthesis, we collected the following information, which was used in the bibliometric analysis: title, authors, journal, DOI, type of publication, national affiliation of Latin American researchers, and topic of publication.

2.3. Data analysis

We summarized information from the collected publications according to the type of publication, the topic of publication, and the national affiliation in the “Bibliometric analysis” section. The first purpose of this section was to quantify contributions of the region in the global context, and the contribution by country in the regional context. The second purpose was to classify the publications by topic and type, which allowed us to organize the next sections of this literature review. In the following two sections, “Phylogenetic and molecular understanding” and “medical contributions”, we compiled information from research articles and reviews. The last section, called “Additional concerns”, was included to highlight contributions not covered in the two
main topics, but discussed in the remaining publications (commentaries, letters to the editor, editorials, communications, perspectives, points of view, and contributions).

3. Bibliometric analysis

Following the PRISMA guidelines shown in Figure 1, we found 301 publications in the considered databases; this number decreased to 161 after excluding duplicates. Later, we manually excluded eight additional publications due to affiliations from New Mexico (1) and Pennsylvania (7) were confused with Mexico and Panama, respectively. Therefore, this qualitative analysis included 153 publications, which contained at least one researcher with Latin American affiliation (see Supplementary S1 file for complete information of publications). We highlight that several publications were not exclusively submitted by Latin American researchers, some of which are part of research groups together with North American, European, or Asian researchers. Figure 2 presents the classification of publications by type, where most of them were letters to the editor or commentaries, editorials, and research articles.

Regardless of the number of authors from the same country but different institutions, among all publications, we highlight that 15 of them were submitted by groups in which there were researchers from at least two Latin American countries. Therefore, these publications were counted for each nation involved; thus, these 15 publications have 56 national affiliations. Most of these publications were due to the Latin American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-19), which was created to integrate the region around this new outbreak (Rodríguez-Morales et al., 2020d). The remaining 138 publications were submitted by groups in which there were researchers from a single Latin American country. Therefore,
these publications were counted once for the country, disregarding whether they were submitted
by one or more researchers with the same national affiliation; in other words, these 138
publications have 138 national affiliations. In summary, the 153 publications accounted for 194
national affiliations. Figure 3 shows publications by national affiliation, where Brazil had the
highest contribution with 80 publications, followed by Colombia, Mexico, and Argentina, with
36, 18, and 14 publications, respectively. Conversely, the following Latin American countries
had no publications: Cuba, Costa Rica, Dominican Republic, El Salvador, Guatemala, Haiti, and
Nicaragua.

We did the same search without the affiliation field restriction. We found 1224, 615, 3538, 1841,
665, 48, 2627, and 34 publications in Scopus, Web of Science, PubMed, ScienceDirect, Wiley,
Sage, LILACS, and SciELO databases, respectively. Hence, publications with Latin American
researchers in these databases, Figure 1, represent 2.9%, 3.1%, 2.8%, 3.3%, 2.9%, 2.1%, 1.6%,
and 76.5% of all publications, respectively. Excluding Scielo, which is a Latin American
database, the contribution of the region was 2.7±0.6%. This low value could be associated with
the science gap (gap in science funding, technology, facilities) between the region and the
developed countries. However, other possibilities are the late coronavirus appearance in the
region (between February and March), as opposed to the initial outbreak (December 2019) and
the number of Latin American cases (nearly 4% world total), as shown in Table 1.

Finally, Figure 4 shows the classification of publications by topic, which were medical
considerations (surgery recommendations, diagnosis, comorbidities, medical guidelines,
dentistry considerations, among others), social and environmental considerations, general aspects
(zoonotic links, spreading, origin, disease, surveillance, among others), epidemiological
analyses, bioinformatics (molecular and phylogenetic analyses, molecular simulations, genetic
annotations, among others), mental health considerations, search for potential treatments, and
meta-analyses. Excluding the general aspects, the remaining topics are shown in the following
sections.

4. Phylogenetic and molecular understanding

The researcher with the highest number of research articles was Ph.D. Marta Giovanetti, who has
contributed to SARS-CoV-2 understanding through bioinformatic analyses (Angeletti et al.,
2020; Benvenuto et al., 2020a; Benvenuto et al., 2020b; Benvenuto et al., 2020c; Benvenuto et
al., 2020d; Cleemput et al., 2020; Giovanetti et al., 2020a; Giovanetti et al., 2020b). Her first
research focused on a phylogenetic analysis of SARS-CoV-2, finding that among the viruses
compared, this virus is closely related to bat-SL-CoVZXC21 (GenBank ID MG772934.1), while
the least related is MERS (Benvenuto et al., 2020b). However, Cardenas-Conejo et al. (2020)
proposed that SARS-CoV-2 has a closer relation to bat-SL-CoV-RaTG13 (GenBank ID
MN996532.1), then, authors suggested first that SARS-CoV-2 is unlikely to come directly from
pangolin viruses, and second, that if SARS-CoV-2 has a recombinant origin, this recombination
did not happen in ORF1ab. Nevertheless, both Benvenuto et al. (2020b) and Cardenas-Conejo et
al. (2020) concluded that the novel virus could come from a bat SARS-like coronavirus isolate,
which is in agreement with reports from the GISAID database (Hadfield et al., 2018; Sagulenko
et al., 2018).

Subsequent studies of the Giovanetti group found differences in the superficial spike protein S of
SARS-CoV-2 through structural analyses, which could give a higher ability to infect humans
when compared to other coronaviruses (Benvenuto et al., 2020b). This ability could be attributed
to two mutations found in the non-structural protein 2 (nsp2) and nsp3, both originating from a
possible positive pressure (Angeletti et al., 2020). Similarly, evaluating in silico molecular interactions between the human angiotensin-converting enzyme 2 (ACE2) receptor and the spike protein of some coronaviruses, Ortega et al. (2020a) found that SARS-CoV-2 has some modified residues. Such residues could improve the recognition and interaction with the ACE2 receptor, providing SARS-CoV-2 with a higher infectiousness, which is in agreement with another study published simultaneously (Andersen et al., 2020). Likewise, performing in silico molecular interactions, Ortega et al. (2020b) evaluated the interaction between the protease of SARS-CoV-2 and some protease inhibitors as a strategy to control COVID-19 infection. The most energetic interactions predicted were using Saquinavir, Lopinavir, and Tipranavir, which are treatments for HIV patients; however, experimentation is required to validate these simulations.

In a later study, the Giovanetti group analyzed SARS-CoV-2 mutations through time, finding two variations located in nsp6 and ORF10, which could be caused by a positive selective pressure, leading to a lower protein structure stability and possibly (awaiting for evidence) a higher virulence (Benvenuto et al., 2020a). Cardenas-Conejo et al. (2020) similarly detected variations in nsp6 and eight deleted amino acids in nsp1 from some Japanese virus strains. Although these in silico studies are a first approach and require experimental validation (Ciccozzi et al., 2020), they could also be a first step to aid in identifying treatments or vaccines.

Lastly, Giovanetti simultaneously contributed to another research group to develop and validate an open-access tool, called the Genome Detective Coronavirus Typing Tool, which analyzes SARS-CoV-2 genomes to generate new knowledge of COVID-19 outbreak (Cleemput et al., 2020).

Concerning the sequencing of SARS-CoV-2 genomes to understand this novel coronavirus, some Latin American researchers have contributed to the publication of sequences of isolated strains.
from countries such as Chile (Castillo et al., 2020) or Nepal (Sah et al., 2020). Researchers from other countries have also sequenced the genomes of strains from Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Panama, Peru, and Uruguay, totaling 98 genome sequences until April 20, 2020 (see Supplementary S2 file for detailed information of all sequences). The GISAID database has these 98 sequences collected along with 10,380 others, meaning that Latin American contribution is near 0.94% (Hadfield et al., 2018; Sagulenko et al., 2018). Table 2 summarizes this information by country, showing that Brazil and Mexico have the highest number of sequenced genomes, 52 and 17, respectively. Figure 5 presents some of the Latin American SARS-CoV-2 strains in the phylogenetic tree, evidencing the high heterogeneity among them because they belong to different clades.

5. Medical contributions

5.1. Epidemiological analyses

Studies to track first cases in different countries have been performed, such as the case of tracing the first cases of COVID-19 in countries like Italy (Giovanetti et al., 2020b) and Chile (Castillo et al., 2020) using phylogenetic analyses. Both studies found that the first cases came from China and Europe since S and G variants of SARS-CoV-2 were detected. In the case of Italy, a reentry from Germany was detected (Giovanetti et al., 2020a). Tracing of imported cases to other Latin American countries has also been performed using strategies such as data recovery of international flights from the most affected countries to Brazil (Candido et al., 2020), or recompilation of epidemiological data from hospitals in Bolivia (Escalera-Antezana et al., 2020). Both studies concluded that the first imported cases came from Europe, specifically from Italy and Spain. Moreover, other bioinformatics tools have been used to contribute to epidemiological
understanding. For example, a Bayesian phylogeographic reconstruction suggested that Wuhan
was effectively the outbreak epicenter on November 25, 2019, spreading later to other Chinese
regions (Benvenuto et al., 2020c).

Additionally, the geo-positioning of some cases and the heterogeneity of the outbreak progress
among countries, with demographic similarities, have been reported (de Figueiredo et al., 2020;
Xu et al., 2020). Other epidemiological studies have been done to predict the COVID-19
spreading (Benvenuto et al., 2020d; Córdova-Lepe et al., 2020; González-Jaramillo et al., 2020;
Manrique-Abril et al., 2020), which concluded that containment strategies are required to avoid
overspreading in countries like Chile and Colombia. Similarly, Kraemer et al. (2020) analyzed
the effect of mobility in China before and after the sanitary containment of Wuhan in the
COVID-19 spreading in this country; they demonstrated that decreasing mobility favors the
reduction of COVID-19 spreading.

5.2. Meta-analyses performed

Latin American researchers have also published meta-analyses of clinical, laboratory, and image
data from reported COVID-19 cases (Borges do Nascimento et al., 2020; Rodriguez-Morales et
al., 2020b). On the one hand, the meta-analysis submitted by Rodriguez-Morales et al. (2020b)
on February 29, 2020, used 19 articles with 2,874 patients for quantitative analyses. On the other
hand, the meta-analysis of Borges do Nascimento et al. (2020), submitted six days later,
employed 61 studies with 59,254 patients. Both revisions included the most common symptoms
as well as typical abnormalities observed in chest radiographs and computed tomographies,
which were like other respiratory illnesses and viral pneumonia, making it difficult to distinguish
from them (Borges do Nascimento et al., 2020). Oxygen support in critical patients was also
analyzed, where Borges do Nascimento et al. (2020) suggested that excluding the non-invasive ventilation usage since no evidence supports its benefits.

Regarding lethality, the most affected population (81%) was the older group (60 years or more), but additional information is required to understand the COVID-19 impact on other continents because most of the data used in these meta-analyses came from China. Therefore, meta-analyses using Latin American cases would also be ideal for determining how COVID-19 could affect this region, which has some differences, such as lower average age or higher exposure to respiratory infections than other regions like Europe (Amariles et al., 2020a). A third meta-analysis was found, which suggested that it could be possible to predict if a patient with COVID-19 can present complications. Lagunas-Rangel (2020) suggested that complications are related to high levels of neutrophil-to-lymphocyte ratio (NLR) and low levels of lymphocyte-to-C-reactive protein ratio (LCR).

5.3. Search for potential treatments

Concerning treatments to respiratory issues, Khoury et al. (2020) revised respiratory therapies for COVID-19 patients using cell-based treatments such as mesenchymal stem cells (MSCs), derivatives, or other cells, which have shown positive results in pre-clinical models of influenza. Conversely, they argued that there were few coronavirus studies, such as the case of seven COVID-19 patients in Beijing treated with MSCs, who showed apparent improvements up to 4 days after treatment, but lacked detailed information (Leng et al., 2020). Therefore, after a systematic search in databases, Khoury et al. (2020) found 27 ongoing treatments with 1,287 patients. The authors also highlighted the importance of following ethical protocols for these types of treatments.
Besides the previously mentioned review, since currently there are no approved treatments or vaccines for COVID-19, other revisions have summarized the development of clinical trials for COVID-19 treatments. This is the case of the search made by Rosa & Santos (2020), who looked for ongoing clinical trials in Clinicaltrials.gov. The authors used some constraints in their search, such as low cost, reduced time to reach markets, existing pharmaceutical supplies, or the possibility to combine with other drugs. In total, 24 clinical trials were found, most of them in clinical phases 2, 3, or 4, with a scheduled end in 2020. These ongoing clinical trials are using chloroquine, hydroxychloroquine, human immunoglobulin, remdesivir, arbidol, lopinavir, ritonavir, oseltamivir, darunavir, cobicistat, interferons, carrimycin, danoprevir, xiyangping, favipiravir, thalidomide, vitamin C, methylprednisolone, pirfenidone, bromhexie, bevacizumab, fingolimod, and traditional Chinese medicines (TCM).

Similarly, Serafin et al. (2020) searched for new treatments for coronaviruses like SARS-CoV, SARS-CoV-2, and HCoV-OC43 in PubMed, SCOPUS, and Web of Science databases. The drugs found as SARS-CoV-2 treatments are captopril, chloroquine, clomipramine, disulfiram, enalapril, hydroxychloroquine, mefloquine, metformin, nitazoxanide, remdesivir, and teicoplanin. This review highlighted positive results using chloroquine, hydroxychloroquine, teicoplanin, and hydroxychloroquine in conjunction with azithromycin. Finally, Rosales-Mendoza (2020) suggested that a potential treatment with biotechnological origin could be produced using plant species as hosts.

5.4. Medical considerations

Most medical articles studied populations at risk and comorbidities, also provided recommendations and guidelines for medical personnel. Rascado Sedes et al. (2020) developed a
contingency plan that allows an optimal response of the intensive care units (ICU) to the pandemic. The plan considers possible scenarios, the need for human and technical resources, communication and information, optimized use of resources, and personal protective equipment (PPE).

Healthcare workers, emergency room physicians, anesthesiologists, dentists, ophthalmologists, head and neck surgeons, maxillofacial surgeons, and otolaryngologists are among the most vulnerable ones because they perform procedures that can aerosolize secretions (Kowalski et al., 2020). According to several studies, articles, and protocols, Boccalatte et al. (2020) summarized recommendations related to PPE, mandatory use of protective suits, head covers, eye protection, mask, gloves, and N95, FFP2, or PAPR masks, personnel training, and techniques or manoeuvres for different medical practices.

Concerning surgeries, although there is no information about to translate risks to the operating room team during such procedures to COVID-19 patients, the recommendation is to postpone them (Cohen et al., 2020; Ducournau et al., 2020). The situations in which a delay in the surgical procedure may affect the patient, such as some oncologic or organ transplant surgeries, surgery must be performed following strict preventive measures. In the case of unpostponable abdominal surgeries, a laparotomic operation with regional anesthesia should be preferred (Carneiro et al., 2020; Cohen et al., 2020; Correia et al., 2020; Quintão et al., 2020). Other articles summarized protocols and recommendations for hand (Ducournau et al., 2020), head and neck (Kowalski et al., 2020), and urologic surgeries (Puliatti et al., 2020).

Researchers have also performed literature reviews concerning populations with higher risk due to comorbidities. First, Hussain et al. (2020) focused on patients with diabetes mellitus and COVID-19. They summarized the different determinants that associate this pathology with
greater severity and death, as well as the importance of multidisciplinary medical management. The authors mentioned that COVID-19 could cause pancreatic damage, which could affect patients with diabetes. Likewise, the positive effects of hydroxychloroquine and chloroquine on diabetic patients were mentioned, such as reducing insulin degradation tending to normalize glucose levels. Therefore, in case hydroxychloroquine or chloroquine is administered, antidiabetic drug doses should be readjusted to avoid hypoglycemic events. The authors also mentioned the necessity to continue studying in these patients the chronic inflammation, immune response, coagulation activity, and vascular permeability, as well as whether hyperglycemia or hypoglycemia can alter the virulence of SARS-CoV-2, or whether the virus itself interferes with insulin secretion or glycemic control. All this information will be needed to propose adequate clinical treatments.

Likewise, Puliatti et al. (2020) considered the effect of SARS-CoV-2 in different organs of the urinary tract. They highlighted that ACE2-positive cells (target of SARS-CoV-2 spike proteins) have been found in these organs, which could have a high risk of affectation, even leading to death, which explains the kidney damage experimented in some COVID-19 patients. Similarly, chronic hemodialysis patients are also at particular risk due to their immunosuppression status, advanced age, and comorbidities coexistence. Vega-Vega et al. (2020) summarized the recommendations for these patients proposed by three international organizations: Center for Disease Control and Prevention (CDC), the Spanish Society of Nephrology, and the Latin American Society of Nephrology and Hypertension, to which were added suggestions of some experts. Some recommendations are the proper definition of cases, guidelines for patients and family, scrutiny of suspicious COVID-19 cases and their management within hemodialysis units, PPE employment, and sanitation of surfaces and devices.
Another group at risk mentioned by researchers is related to critical COVID-19 patients who need assisted ventilation. Some authors recommend taking into account some considerations before using high-flow nasal oxygen therapy, non-invasive ventilation, or extracorporeal membrane oxygenation (ECMO), the latter being a treatment that no all medical centers can afford. First, if the medical center has adequate protection levels for health workers from exhaled air dispersed, and second, the impact of treatment on acute respiratory distress syndrome (ARDS) (Bartlett et al., 2020; őNamendys-Silva, 2020a; őNamendys-Silva, 2020b). Similarly, Chica-Meza et al. (2020) summarized conventional and non-conventional respiratory therapies in critical COVID-19 patients, including recommendations and considerations. Finally, surveys have been performed to identify COVID-19 impacts in patients at risk, such as pediatric patients with cancer (Hrusak et al., 2020), but the information is still limited; however, the recommendation is to follow the same medical practices described previously.

5.5. Mental health considerations

Mental health care must be considered, given that quarantine can cause boredom, loneliness, anger, anxiety, depression, and stress. Patients and health workers should have mental health services (Carvalho et al., 2020b; Lima et al., 2020). In especial when more people can be affected by mental issues during the outbreak than by the outbreak itself (Ornell et al., 2020), and previous outbreaks have caused post-traumatic stress disorder (PTSD) in health workers (Torales et al., 2020).

Concerning performed studies on mental issues, first, Fonseca et al. (2020) established recommendations for patients with schizophrenia. Among recommendations are an adequate identification of COVID-19 symptoms, prevention of worsening of psychiatric symptoms,
relapses due to the closed environment, fear of disease and isolation, use of telemedicine, 

promoting adherence to antipsychotic medication regimens, reducing emotional distress, hygiene 

practices, and family support. Finally, Carvalho et al. (2020a), using questionnaires to Brazilians, 

investigated whether extroverted and conscientious people are engaged with the containment 

measures implemented during the COVID-19 pandemic. They found that extroverted people 

seem to lack commitment to containment measures, while people with conscientiousness 

personality tend to follow recommendations. Therefore, at least in Brazil, strategies for 

extroverted people should be proposed to avoid they become transmission vectors. However, the 

idiosyncrasy is similar throughout Latin America; thus, these strategies should be required in the 

entire region.

6. Additional Concerns

6.1. Social and environmental concerns

- Telemedicine should be considered as an alternative to patient attention to avoid COVID-19 

  spreading. However, this strategy is limited because of the scarce existence of telemedicine 

  systems; thus, social media could be used (Assis Machado et al., 2020; Quintão et al., 2020).

- Elachola et al. (2020) highlighted that there are no prevalence and effectiveness studies on 

  using facemasks related to the COVID-19 outbreak. This information could be useful in 

  providing recommendations about their usage. However, based on past outbreaks, the 

  evidence did not show positive or negative effects when the population used facemasks 

  (Stern et al., 2020).

- Since the first COVID-19 cases reported in Latin America, fake news and misinformation 

  have increased, where even treatments with potential health affectations have been proposed,
as in the case of using chloroform or ether as alleged COVID-19 treatments (Lana et al., 2020; Martins & Santos, 2020). Additionally, information should be verified, avoiding panic spreading, which has caused panic buying of supplies and medications (Cuan-Baltazar et al., 2020).

- The quick COVID-19 spreading in different regions and countries could cause that health workers to become overwhelmed, therefore training new personal, although challenging, is a necessity that could help to attend the current outbreak. Additionally, the pharmacy workforce should be prepared as they are the first ones to attend possible cases of infection (Amariles et al., 2020b; Aruru et al., 2020; Haines et al., 2020).

- Countries with low or middle incomes, such as Latin American countries, may have already saturated their health systems. Hence, the COVID-19 outbreak could oversaturate them (Carneiro et al., 2020), which can be exacerbated by the lack of government preparation and social policies, such as the Ecuadorian case (Hallo et al., 2020).

- Based on events that occurred with the “Diamond Princess” cruise, alternatives should be proposed to quarantine people from other cruises and illegal immigrants entering a country (Sawano et al., 2020).

- Due to the current outbreak, many activities have been interrupted, which joined the socioeconomic limitations of vulnerable groups, could lead to food insecurity in these populations, who even have no access to clean water (Oliveira et al., 2020).

- Knowing that COVID-19 has a zoonotic origin, One Health approach has taken relevance, which seeks integrative studies where the health of humans, environment, and animals are considered to understand the virus environment, allowing the prevention or mitigation of future outbreaks (Bonilla-Aldana et al., 2020a).
6.2. Medical concerns

- Initial reports of some pathologies such as rheumatic diseases or neuromyelitis optica spectrum disorder (NMOSD) have shown that they do not increase the risk of complications like other comorbidities. However, further studies are needed (Carnero Contentti & Correa, 2020; Figueroa-Parra et al., 2020).

- Angiotensin II receptor blockers (ATII-RB) are hypertensive drugs that increase ACE2 expression; therefore, there is a possibility that they can favor the internalization of SARS-CoV-2 within the cell; thus, further studies are required. However, suspending ATII-RB therapy may cause even higher affectations than COVID-19 itself; the risk-benefit ratio should be evaluated. In case doctors consider suspending it, there are other options like thiazide diuretics drugs (Gracia-Ramos, 2020; Marin, 2020).

- As previously mentioned, chloroquine and hydroxychloroquine are in vitro inhibitors of SARS-CoV-2 infection. However, concerns are focused on whether these medications could decrease viral load or prevent infection, clinical disease, clinical severity, or even death. Other factors, such as side effects, should also be considered (Kim et al., 2020; Monteiro et al., 2020; Picot et al., 2020).

- COVID-19 mainly affects the respiratory system, but it can also alter the central nervous system. Hence, possible affectations in the respiratory center could exacerbate respiratory distress caused by pulmonary affectation (Conde et al., 2020).

- Tropical countries affected by dengue could face two outbreaks at the same time, dengue and COVID-19, which could affect the population, even coinfecting some patients simultaneously. Both outbreaks will require the intensive attention of health systems to avoid...
a crossed affection between them, which can be challenging and overwhelming for the
health systems (Lorenz et al., 2020; Navarro et al., 2020; Rodriguez-Morales et al., 2020c;
Saavedra-Velasco et al., 2020).

- As SARS-CoV-2 can remain in saliva, oral health professionals require research focused on
the influence of COVID-19 in their activities to take appropriate measures. However, the
recommendation is to stop dental treatments (Martelli-Júnior et al., 2020; Napimoga &
Freitas, 2020; Sabino-Silva et al., 2020).

- Strategies during intubation are not the only important ones to avoid COVID-19 spreading in
health workers during medical procedures; strategies for extubation are also required
(Trujillo, 2020).

- There is no evidence that immunosuppressant treatments (ITS) could decrease or increase the
risk of severe COVID-19 infection; therefore, further investigation is recommended. In case
treatments are suspended, factors such as potential issues on patients should be considered
(Carnero Contentti & Correa, 2020).

- There is limited evidence of COVID-19 effect on pregnant women; hence, cases of pregnant
women with COVID-19 should be studied to understand the clinical impact of the infection
(Zambrano et al., 2020).

Conclusions

Although our purpose was to give visibility to the contribution of Latin American researchers in
the knowledge generation related to the COVID-19 outbreak, this review has two drawbacks.
The first is the continuous availability of new publications; therefore, an observation window
was employed. Second, several Latin American researchers are currently working on other
continents without a Latin American affiliation, making them impossible to track. However, after this literature review, we were able to evidence the active participation of Latin American researchers in different subjects, whether as members of national, regional (LANCOVID-19), or even international research groups. Concerning our findings, the publications evidenced that these research groups have advanced in molecular and medical subjects, mainly in genetic understanding, epidemiological behaviors, meta-analyses, interaction between COVID-19 and other pathologies, and recommendations to medical procedures. Finally, understanding that this health crisis requires the commitment of as many researchers as possible, our wish is that the contribution of Latin American researchers continues to grow. Some topics with regional and global interest for future studies include \textit{in silico} analyses of potential treatments and their respective \textit{in vitro} and \textit{in vivo} validations, meta-analysis of Latin American patients, and epidemiological surveillances. Regarding medical considerations, a deeper understanding of the COVID-19 interaction with risk comorbidities is needed to propose adequate clinical treatments. The same applies to unexplored/underexplored physical and mental pathologies, such as dengue.

\section*{Acknowledgments}

This review is in memory of all deceased by the COVID-19 outbreak.

\section*{References}

Amariles P, Granados J, Ceballos M, and Montoya CJ. 2020a. COVID-19 in Colombia endpoints. Are we different, like Europe? \textit{Research in Social and Administrative Pharmacy}. DOI 10.1016/j.sapharm.2020.03.013.
Amariles P, Ledezma-Morales M, Salazar-Ospina A, and Hincapié-García JA. 2020b. How to link patients with suspicious COVID-19 to health system from the community pharmacies? A route proposal. Research in Social and Administrative Pharmacy. DOI 10.1016/j.sapharm.2020.03.007.

Andersen KG, Rambaut A, Lipkin WI, Holmes EC, and Garry RF. 2020. The proximal origin of SARS-CoV-2. Nature Medicine. DOI 10.1038/s41591-020-0820-9.

Angeletti S, Benvenuto D, Bianchi M, Giovanetti M, Pascarella S, and Ciccozzi M. 2020. COVID-2019: The role of the nsp2 and nsp3 in its pathogenesis. Journal of Medical Virology. DOI 10.1002/jmv.25719.

Aruru M, Truong H-A, and Clark S. 2020. Pharmacy Emergency Preparedness and Response (PEPR) framework for expanding pharmacy professionals’ roles and contributions to emergency preparedness and response during the COVID-19 pandemic and beyond. Research in Social and Administrative Pharmacy. DOI 10.1016/j.sapharm.2020.04.002.

Assis Machado R, Lins de Souza N, Maria Oliveira R, Martelli Júnior H, and Rogério Ferreti Bonan P. 2020. Social Media and telemedicine for oral diagnosis and counselling in the COVID-19 Era. Oral Oncology:104685. DOI 10.1016/j.oraloncology.2020.104685.

Bartlett RH, Ogino MT, Brodie D, McMullan DM, Lorusso R, MacLaren G, Stead CM, Rycus P, Fraser JF, Belohlavek J, Salazar L, Mehta Y, Raman L, and Paden ML. 2020. Initial ELSO Guidance Document: ECMO for COVID-19 Patients with Severe Cardiopulmonary Failure. ASAIO Journal: Artificial Organ Research and Development Online First. DOI 10.1097/mat.0000000000001173.

Benvenuto D, Angeletti S, Giovanetti M, Bianchi M, Pascarella S, Cauda R, Ciccozzi M, and Cassone A. 2020a. Evolutionary analysis of SARS-CoV-2: how mutation of Non-
Structural Protein 6 (NSP6) could affect viral autophagy. *Journal of Infection*. DOI 10.1016/j.jinf.2020.03.058.

Benvenuto D, Giovanetti M, Ciccozzi A, Spoto S, Angeletti S, and Ciccozzi M. 2020b. The 2019-new coronavirus epidemic: Evidence for virus evolution. *Journal of Medical Virology* 92:455-459. DOI 10.1002/jmv.25688.

Benvenuto D, Giovanetti M, Salemi M, Prosperi M, De Flora C, Alcantara LC, Angeletti S, and Ciccozzi M. 2020c. The global spread of 2019-nCoV: a molecular evolutionary analysis. *Pathogens and Global Health*. DOI 10.1080/20477724.2020.1725339.

Benvenuto D, Giovanetti M, Vassallo L, Angeletti S, and Ciccozzi M. 2020d. Application of the ARIMA model on the COVID-2019 epidemic dataset. *Data in Brief* 29. DOI 10.1016/j.dib.2020.105340.

Boccalatte LA, Larrañaga JJ, Perez Raffo GM, Teijido CA, García Fornari G, Staneloni MI, and Figari MF. 2020. Brief guideline for the prevention of COVID-19 infection in head and neck and otolaryngology surgeons. *American Journal of Otolaryngology* 102484. DOI 10.1016/j.amjoto.2020.102484.

Bonilla-Aldana DK, Dhama K, and Rodriguez-Morales AJ. 2020a. Revisiting the One Health Approach in the Context of COVID-19: A Look into the Ecology of this Emerging Disease. *Advances in Animal and Veterinary Sciences* 8:234-236. DOI 10.17582/journal.aavs/2020/8.3.234.236.

Bonilla-Aldana DK, Quintero-Rada K, Montoya-Posada JP, Ramirez-Ocampo S, Paniz-Mondolfi A, Rabaan AA, Sah R, and Rodriguez-Morales AJ. 2020b. SARS-CoV, MERS-CoV and now the 2019-novel CoV: Have we investigated enough about coronaviruses? - A
Borges do Nascimento JI, Cacic N, Abdulazeem MH, von Groote CT, Jayarajah U, Weerasekara I, Esfahani AM, Civile TV, Marusic A, Jeroncic A, Carvas Junior N, Pericic PT, Zakarija-Grkovic I, Meirelles Guimarães MS, Luigi Bragazzi N, Bjorklund M, Sofi-Mahmudi A, Altujjar M, Tian M, Arcani MD, O’Mathúna PD, and Marcolino SM. 2020. Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis. *Journal of Clinical Medicine* 9. DOI 10.3390/jcm9040941.

Candido DDS, Watts A, Abade L, Kraemer MUG, Pybus OG, Croda J, Oliveira W, Khan K, Sabino EC, and Faria NR. 2020. Routes for COVID-19 importation in Brazil. *Journal of travel medicine*. DOI 10.1093/jtm/taaa042.

Cardenas-Conejo Y, Linan-Rico A, Garcia-Rodriguez DA, Centeno-Leija S, and Serrano-Posada H. 2020. An exclusive 42 amino acid signature in pp1ab protein provides insights into the evolutive history of the 2019 novel human-pathogenic coronavirus (SARS-CoV-2). *Journal of Medical Virology*. DOI 10.1002/jmv.25758.

Carneiro A, Wroclawski M, Nahar B, Soares A, Cardoso A, Kim N, and Carvalho F. 2020. Impact of the COVID-19 Pandemic on the Urologist’s clinical practice in Brazil: a management guideline proposal for low- and middle-income countries during the crisis period. *International Brazilian Journal of Urology* 46. DOI 10.1590/S1677-5538.IBJU.2020.04.03.

Carnero Contentti E, and Correa J. 2020. Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge. *Multiple Sclerosis and Related Disorders* 41:102097. DOI 10.1016/j.msard.2020.102097.
Carvalho LdF, Pianowski G, and Gonçalves AP. 2020a. Personality differences and COVID-19: are extroversion and conscientiousness personality traits associated with engagement with containment measures? *Trends in Psychiatry and Psychotherapy*. DOI 10.1590/2237-6089-2020-0029.

Carvalho PMdM, Moreira MM, de Oliveira MNA, Landim JMM, and Neto MLR. 2020b. The psychiatric impact of the novel coronavirus outbreak. *Psychiatry Research* 286:112902. DOI 10.1016/j.psychres.2020.112902.

Castillo AE, Parra B, Tapia P, Acevedo A, Lagos J, Andrade W, Arata L, Leal G, Barra G, Tambley C, Tognarelli J, Bustos P, Ulloa S, Fasce R, and Fernández J. 2020. Phylogenetic analysis of the first four SARS-CoV-2 cases in Chile. *Journal of Medical Virology* n/a. DOI 10.1002/jmv.25797.

Ciccozzi M, Benvenuto D, Giovanetti M, Bianchi M, Pascarella S, and Angeletti S. 2020. Response to Ribeiro da Silva et al., “Role of Nonstructural Proteins in the Pathogenesis of SARS-CoV-2.” *Journal of Medical Virology* n/a. DOI 10.1002/jmv.25863.

Ciotti M, Angeletti S, Minieri M, Giovannetti M, Benvenuto D, Pascarella S, Sagnelli C, Bianchi M, Bernardini S, and Ciccozzi M. 2020. COVID-19 Outbreak: An Overview. *Chemotherapy*. DOI 10.1159/000507423.

Cleemput S, Dumon W, Fonseca V, Karim WA, Giovanetti M, Alcantara LC, Deforche K, and de Oliveira T. 2020. Genome Detective Coronavirus Typing Tool for rapid identification and characterization of novel coronavirus genomes. *Bioinformatics*. DOI 10.1093/bioinformatics/btaa145.
Cohen SL, Liu G, Abrao M, Smart N, and Heniford T. 2020. Perspectives on Surgery in the time of COVID-19: Safety First. *Journal of Minimally Invasive Gynecology*. DOI 10.1016/j.jmig.2020.04.003.

Conde G, Quintana Pájaro LD, Quintero Marzola ID, Villegas YR, and Moscote Salazar LR. 2020. Neurotropism of SARS-CoV 2: Mechanisms and manifestations. *Journal of the Neurological Sciences*:116824. DOI 10.1016/j.jns.2020.116824.

Córdova-Lepe F, Gutiérrez-Aguilar R, and Gutiérrez-Jara JP. 2020. Number of COVID-19 cases in Chile at 120 days with data at 21/03/2020 and threshold of daily effort to flatten the epi-curve. *Medwave* 20:e7861. DOI 10.5867/medwave.2020.02.7861.

Correia MITD, Ramos RF, and Bahten LCV. 2020. Os cirurgiões e a pandemia do COVID-19. *Revista do Colégio Brasileiro de Cirurgiões* 47. DOI 10.1590/0100-6991e-20202536.

Cuan-Baltazar JY, Muñoz-Perez MJ, Robledo-Vega C, Pérez-Zepeda MF, and Soto-Vega E. 2020. Misinformation of COVID-19 on the Internet: Infodemiology Study. *JMIR Public Health Surveill* 6:e18444. DOI 10.2196/18444.

Cupertino MC, Resende MB, Mayers NAJ, Carvalho LM, and Siqueira-Batista R. 2020. Emerging and re-emerging human infectious diseases: A systematic review of the role of wild animals with a focus on public health impact. *Asian Pacific Journal of Tropical Medicine* 13:99-106. DOI 10.4103/1995-7645.277535.

Chica-Meza C, Peña-López LA, Villamarin-Guerrero HF, Moreno-Collazos JE, Rodríguez-Corredor LC, Lozano WM, and Vargas-Ordonez MP. 2020. Cuidado Respiratorio En Covid-19. *Acta Colombiana de Cuidado Intensivo*. DOI 10.1016/j.acci.2020.04.001.
de Figueiredo AM, Codina AD, de Figueiredo DCMM, Gil-García E, and Kalache A. 2020. Letalidad del COVID-19: ausencia de patrón epidemiológico. *Gaceta Sanitaria*. DOI 10.1016/j.gaceta.2020.04.001.

Diaz-Quijano FA, Rodríguez-Morales AJ, and Waldman EA. 2020. Translating transmissibility measures into recommendations for coronavirus prevention. *Revista de Saúde Pública* 54. DOI 10.11606/s1518-8787.2020054002471.

Ducournau F, Arianni M, Awwad S, Baur EM, Beaulieu JY, Bouldouhnine M, Caloia M, Chagar K, Chen Z, Chin AY, Chow EC, Cobb T, David Y, Delgado PJ, Woon Man Fok M, French R, Golubev I, Haugstvedt JR, Ichihara E, Jorquera RA, Koo SCJJ, Lee JY, Lee YK, Liu YJ, Kaleli T, Mantovani GR, Mathoulin C, Messina JC, Muccioli C, Nazerani S, Ng CY, Obdeijn MC, Van Overstraeten L, Prasetyono TOH, Ross M, Shih JT, Smith N, Suarez RFA, Chan PT, Tiemdjo H, Wahegaonkar A, Wells MC, Wong WY, Wu F, Yang XF, Yanni D, Yao J, and Liverneaux PA. 2020. COVID-19: Initial experience of an international group of hand surgeons. *Hand Surgery and Rehabilitation*. DOI 10.1016/j.hansur.2020.04.001.

Elachola H, Ebrahim SH, and Gozzer E. 2020. COVID-19: Facemask use prevalence in international airports in Asia, Europe and the Americas, March 2020. *Travel Medicine and Infectious Disease*:101637. DOI 10.1016/j.tmaid.2020.101637.

Escalera-Antezana JP, Lizon-Ferrufino NF, Maldonado-Alanoca A, Alarcón-De-la-Vega G, Alvarado-Arnez LE, Balderrama-Saavedra MA, Bonilla-Aldana DK, and Rodriguez-Morales AJ. 2020. Clinical features of cases and a cluster of Coronavirus Disease 2019 (COVID-19) in Bolivia imported from Italy and Spain. *Travel Medicine and Infectious Disease*:101653. DOI 10.1016/j.tmaid.2020.101653.
Figueroa-Parra G, Aguirre-Garcia GM, Gamboa-Alonso CM, Camacho-Ortiz A, and Galarza-Delgado DA. 2020. Are my patients with rheumatic diseases at higher risk of COVID-19? *Annals of the Rheumatic Diseases*. DOI 10.1136/annrheumdis-2020-217322.

Fonseca L, Diniz E, Mendonça G, Malinowski F, Mari J, and Gadelha A. 2020. Schizophrenia and COVID-19: risks and recommendations. *Brazilian Journal of Psychiatry*. DOI 10.1590/1516-4446-2020-0010.

Giovanetti M, Angeletti S, Benvenuto D, and Ciccozzi M. 2020a. A doubt of multiple introduction of SARS-CoV-2 in Italy: A preliminary overview. *Journal of Medical Virology*. DOI 10.1002/jmv.25773.

Giovanetti M, Benvenuto D, Angeletti S, and Ciccozzi M. 2020b. The first two cases of 2019-nCoV in Italy: Where they come from? *Journal of Medical Virology* 92:518-521. DOI 10.1002/jmv.25699.

González-Jaramillo V, González-Jaramillo N, Gómez-Restrepo C, Palacio-Acosta CA, Gómez-López A, and Franco OH. 2020. Proyecciones de impacto de la pandemia COVID-19 en la población colombiana, según medidas de mitigación. Datos preliminares de modelos epidemiológicos para el periodo del 18 de marzo al 18 de abril de 2020. *Revista de Salud Pública* 22. DOI 10.15446/rsap.v22.85789.

Gracia-Ramos AE. 2020. Is the ACE2 Overexpression a Risk Factor for COVID-19 Infection? *Archives of Medical Research*. DOI 10.1016/j.arcmed.2020.03.011.

Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, Sagulenko P, Bedford T, and Neher RA. 2018. NextStrain: Real-time tracking of pathogen evolution. *Bioinformatics* 34:4121-4123. DOI 10.1093/bioinformatics/bty407.
Haines A, de Barros EF, Berlin A, Heymann DL, and Harris MJ. 2020. National UK programme of community health workers for COVID-19 response. *The Lancet* 395:1173-1175. DOI 10.1016/S0140-6736(20)30735-2.

Hallo A, Rojas A, and Hallo C. 2020. Perspective from Ecuador, the Second Country with More Confirmed Cases of Coronavirus Disease 2019 in South America: A Review. *Cureus* 12. DOI 10.7759/cureus.7452.

Hrusak O, Kalina T, Wolf J, Balduzzi A, Provenzi M, Rizzari C, Rives S, del Pozo Carlavilla M, Valerio Alonso ME, Domínguez Pinilla N, Bourquin J-P, Schmiegelow K, Attarbaschi A, Grillner P, Mellgren K, Ten Bosch van der Werff J, Pieters R, Brozou T, Borkhardt A, Escherich G, Lauten M, Stanulla M, Smith O, Juh Yeoh AE, Elitzur S, Vora A, Li C-K, Ariffin H, Kolenova A, Dallapozza L, Farah R, Lazic J, Manabe A, Styczynski J, Kovacs G, Ottoffy G, Felice M, Buldini B, Conter V, Stary J, and Schrappe M. 2020. Flash Survey on SARS-CoV-2 Infections in Pediatric Patients on anti-Cancer Treatment. *European Journal of Cancer*. DOI 10.1016/j.ejca.2020.03.021.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, and Cao B. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet* 395:497-506. DOI 10.1016/s0140-6736(20)30183-5.

Hussain A, Bhowmik B, and do Vale Moreira NC. 2020. COVID-19 and Diabetes: Knowledge in Progress. *Diabetes Research and Clinical Practice*:108142. DOI 10.1016/j.diabres.2020.108142.
Johns Hopkins University. 2020. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE). Available at https://coronavirus.jhu.edu/map.html.

Khoury M, Cuenca J, Cruz FF, Figueroa FE, Rocco PRM, and Weiss DJ. 2020. Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19. European Respiratory Journal:2000858. DOI 10.1183/13993003.00858-2020.

Kim AHJ, Sparks JA, Liew JW, Putman MS, Berenbaum F, Duarte-García A, Graef ER, Korsten P, Sattui SE, Sirotich E, Ugarte-Gil MF, Webb K, Grainger R, and Alliance† C-GR. 2020. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. Annals of internal medicine:M20-1223. DOI 10.7326/m20-1223.

Kowalski LP, Sanabria A, Ridge JA, Ng WT, de Bree R, Rinaldo A, Takes RP, Mäkitie AA, Carvalho AL, Bradford CR, Paleri V, Hartl DM, Poorten VV, Nixon IJ, Piazza C, Lacy P, Rodrigo JP, Guntinas-Lichius O, Mendenhall WM, D'Cruz A, Lee AWM, and Ferlito A. 2020. COVID-19 pandemic: effects and evidence-based recommendations for otolaryngology and head and neck surgery practice. Head & Neck n/a. DOI 10.1002/hed.26164.

Kraemer MUG, Yang C-H, Gutierrez B, Wu C-H, Klein B, Pigott DM, du Plessis L, Faria NR, Li R, Hanage WP, Brownstein JS, Layan M, Vespignani A, Tian H, Dye C, Pybus OG, and Scarpino SV. 2020. The effect of human mobility and control measures on the COVID-19 epidemic in China. Science:eabb4218. DOI 10.1126/science.abb4218.

Lagunas-Rangel FA. 2020. Neutrophil-to-Lymphocyte ratio and Lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Journal of Medical Virology n/a. DOI 10.1002/jmv.25819.
Lana RM, Coelho FC, Gomes MFDC, Cruz OG, Bastos LS, Villela DAM, and Codeço CT. 2020. The novel coronavirus (SARS-CoV-2) emergency and the role of timely and effective national health surveillance. *Cadernos de saúde publica* 36:e00019620. DOI 10.1590/0102-311x00019620.

Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Shan G, Meng F, Du D, Wang S, Fan J, Wang W, Deng L, Shi H, Li H, Hu Z, Zhang F, Gao J, Liu H, Li X, Zhao Y, Yin K, He X, Gao Z, Wang Y, Yang B, Jin R, Stambler I, Lim LW, Su H, Moskalev A, Cano A, Chakrabarti S, Min K-J, Ellison-Hughes G, Caruso C, Jin K, and Zhao RC. 2020. Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. *Aging and Disease* 11:216-228. DOI 10.14336/ad.2020.0228.

Lima CKT, Carvalho PMDM, Lima IDAAS, Nunes JVADO, Saraiva JS, de Souza RI, da Silva CGL, and Neto MLR. 2020. The emotional impact of Coronavirus 2019-nCoV (new Coronavirus disease). *Psychiatry Research* 287. DOI 10.1016/j.psychres.2020.112915.

Lorenz C, Azevedo TS, and Chiaravalloti-Neto F. 2020. COVID-19 and dengue fever: A dangerous combination for the health system in Brazil. *Travel Medicine and Infectious Disease*:101659. DOI 10.1016/j.tmaid.2020.101659.

Manrique-Abril FG, Agudelo-Calderon CA, González-Chordá VM, Gutiérrez-Lesmes O, Téllez-Piñerez CF, and Herrera-Amaya G. 2020. Modelo SIR de la pandemia de COVID-19 en Colombia. *Revista de Salud Pública* 22. DOI 10.15446/rsap.v22.85977.

Marin GH. 2020. Facts and reflections on COVID-19 and anti-hypertensives drugs. *Drug Discoveries & Therapeutics*. DOI 10.5582/ddt.2020.01017.
Martelli-Júnior H, Machado RA, Martelli DRB, and Coletta RD. 2020. Dental journals and coronavirus disease (COVID-19): A current view. *Oral Oncology:*104664. DOI 10.1016/j.oraloncology.2020.104664.

Martins PR, and Santos VS. 2020. No evidence supports the use of ether and chloroform inhalation for treating COVID-19. *Revista Panamericana De Salud Publica-Pan American Journal of Public Health* 44. DOI 10.26633/rpsp.2020.41.

Millán-Oñate J, Rodriguez-Morales AJ, Camacho-Moreno G, Mendoza-Ramírez H, Rodríguez-Sabogal IA, and Álvarez-Moreno C. 2020. A NEW EMERGING ZOONOTIC VIRUS OF CONCERN: THE 2019 NOVEL CORONAVIRUS (COVID-19). *Infectio* 24. DOI 10.22354/in.v24i3.848.

Monteiro WM, Brito-Sousa JD, Baía-da-Silva D, Melo GCd, Siqueira AM, Val F, Daniel-Ribeiro CT, and Guimarães Lacerda MV. 2020. Driving forces for COVID-19 clinical trials using chloroquine: the need to choose the right research questions and outcomes. *Revista da Sociedade Brasileira de Medicina Tropical* 53. DOI 10.1590/0037-8682-0155-2020.

Napimoga MH, and Freitas ARRd. 2020. Dentistry vs Severe Acute Respiratory Syndrome Coronavirus 2: How to face this enemy. *RGO - Revista Gaúcha de Odontologia* 68. DOI 10.1590/1981-863720200001120200034.

Navarro J-C, Arrivillaga-Henríquez J, Salazar-Loor J, and Rodríguez-Morales AJ. 2020. COVID-19 and dengue, co-epidemics in Ecuador and other countries in Latin America: Pushing strained health care systems over the edge. *Travel Medicine and Infectious Disease:*101656. DOI 10.1016/j.tmaid.2020.101656.
Namendys-Silva SA. 2020a. ECMO for ARDS due to COVID-19. *Heart & Lung*. DOI 10.1016/j.hrtlng.2020.03.012.

Namendys-Silva SA. 2020b. Respiratory support for patients with COVID-19 infection. *The Lancet Respiratory Medicine* 8:e18. DOI 10.1016/s2213-2600(20)30110-7.

Oliveira TC, Abranches MV, and Lana RM. 2020. (In)Segurança alimentar no contexto da pandemia por SARS-CoV-2. *Cadernos de saúde publica* 36. DOI 10.1590/0102-311x00055220.

Ornell F, Schuch JB, Sordi AO, and Kessler FHP. 2020. “Pandemic fear” and COVID-19: mental health burden and strategies. *Brazilian Journal of Psychiatry*. DOI 10.1590/1516-4446-2020-0008.

Ortega JT, Serrano ML, Pujol FH, and Rangel HR. 2020a. Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis. *EXCLI journal* 19:410-417. DOI 10.17179/excli2020-1167.

Ortega JT, Serrano ML, Pujol FH, and Rangel HR. 2020b. Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target. *EXCLI journal* 19:400-409. DOI 10.17179/excli2020-1189.

Palacios Cruz M, Santos E, Velázquez Cervantes MA, and León Juárez M. 2020. COVID-19, una emergencia de salud pública mundial. *Revista Clínica Española*. DOI 10.1016/j.rce.2020.03.001.

Picot S, Marty A, Bienvenu A-L, Blumberg LH, Dupouy-Camet J, Carnevale P, Kano S, Jones MK, Daniel-Ribeiro CT, and Mas-Coma S. 2020. Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. *One Health*:100131. DOI 10.1016/j. onehl t.2020.100131.
Puliatti S, Eissa A, Eissa R, Amato M, Mazzone E, Dell’Oglio P, Sighinolfi MC, Zoeir A, Micali S, Bianchi G, Patel V, Wiklund P, Coelho RF, Bernhard J-C, Dasgupta P, Mottrie A, and Rocco B. 2020. COVID-19 and Urology: A Comprehensive Review of the Literature. *BJU International* n/a. DOI 10.1111/bju.15071.

Quintão VC, Simões CM, Lima LHNe, Barros GAMd, Salgado-Filho MF, Guimarães GMN, Alves RL, Caetano AMM, Schmidt AP, and Carmona MJC. 2020. The Anesthesiologist and COVID-19. *Brazilian Journal of Anesthesiology (English Edition)*. DOI 10.1016/j.bjane.2020.03.002.

Rascado Sedes P, Ballesteros Sanz MÁ, Bodí Saera MA, Carrasco Rodríguez-Rey LF, Castellanos Ortega Á, Catalán González M, de Haro López C, Diaz Santos E, Escriba Barcena A, Frade Mera MJ, Igeño Cano JC, Martín Delgado MC, Martínez Estalella G, Raimondi N, Roca I Gas O, Rodríguez Oviedo A, Romero San Pío E, Trenado Álvarez J, and Raurell M. 2020. Plan de contingencia para los servicios de medicina intensiva frente a la pandemia COVID-19. *Enfermería Intensiva*. DOI 10.1016/j.enfi.2020.03.001.

Rodriguez-Morales AJ, Bonilla-Aldana DK, Tiwari R, Sah R, Rabaan AA, and Dhama K. 2020a. COVID-19, an Emerging Coronavirus Infection: Current Scenario and Recent Developments – An Overview. *Journal of Pure and Applied Microbiology* 14:05-12. DOI 10.22207/JPAM.14.1.02.

Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezaa JP, Alvarado-Arnez LE, Bonilla-Aldana DK, Franco-Paredes C, Henao-Martinez AF, Paniz-Mondolfi A, Lagos-Grisales GJ, Ramírez-Vallejo E, Suárez JA, Zambrano LI, Villamil-Gómez WE, Balbin-Ramon GJ, Rabaan AA, Harapan H, Dhama K, Nishiura H, Kataoka H, Ahmad T, Sah R, and Latin American
Network of Coronavirus Disease C-R. 2020b. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. *Travel Medicine and Infectious Disease*. DOI 10.1016/j.tmaid.2020.101623.

Rodriguez-Morales AJ, Sah R, and Paniz-Mondolfi A. 2020c. Should the Holy Week 2020 be cancelled in Latin America due to the COVID-19 pandemic? *Travel Medicine and Infectious Disease*:101633. DOI 10.1016/j.tmaid.2020.101633.

Rodriguez-Morales AJ, Sánchez-Duque JA, Hernández Botero S, Pérez-Díaz CE, Villamil-Gómez WE, Méndez CA, Verbanaz S, Cimerman S, Rodríguez-Enciso HD, Escalera-Anteza JP, Balbin-Ramón GJ, Arteaga-Lívias FK, Cvetkovic-Vega A, Orduna T, Savio-Larrea E, and Paniz-Mondolfi A. 2020d. Preparación y control de la enfermedad por coronavirus 2019 (COVID-19) en América Latina. *ACTA MEDICA PERUANA* 37. DOI 10.35663/amp.2020.371.909.

Rosa SGV, and Santos WC. 2020. Clinical trials on drug repositioning for COVID-19 treatment. *Revista Panamericana De Salud Publica-Pan American Journal of Public Health* 44. DOI 10.26633/rpsp.2020.40.

Rosales-Mendoza S. 2020. Will plant-made biopharmaceuticals play a role in the fight against COVID-19? *Expert Opinion on Biological Therapy*:null-null. DOI 10.1080/14712598.2020.1752177.

Saavedra-Velasco M, Chiara-Chilet C, Pichardo-Rodriguez R, Grandez-Urbina A, and Inga-Berrospi F. 2020. Coinfección entre dengue y COVID-19: Necesidad de abordaje en zonas endémicas. *Revista de la Facultad de Ciencias Médicas de Córdoba* 77. DOI 10.31053/1853.0605.v77.n1.28031.
Sabino-Silva R, Jardim ACG, and Siqueira WL. 2020. Coronavirus COVID-19 impacts to dentistry and potential salivary diagnosis. *Clinical Oral Investigations*. DOI 10.1007/s00784-020-03248-x.

Sagulenko P, Puller V, and Neher RA. 2018. TreeTime: Maximum-likelihood phylodynamic analysis. *Virus evolution* 4:vex042-vex042. DOI 10.1093/ve/vex042.

Sah R, Rodriguez-Morales AJ, Jha R, Chu DKW, Gu H, Peiris M, Bastola A, Lal BK, Ojha HC, Rabaan AA, Zambrano LI, Costello A, Morita K, Pandey BD, and Poon LLM. 2020. Complete genome sequence of a 2019 novel coronavirus (SARS-COV-2) strain isolated in Nepal. *Microbiology Resource Announcements* 9. DOI 10.1128/mra.00169-20.

Sawano T, Ozaki A, Rodriguez-Morales AJ, Tanimoto T, and Sah R. 2020. Limiting spread of COVID-19 from cruise ships - lessons to be learnt from Japan. *QJM: An International Journal of Medicine*. DOI 10.1093/qjmed/hcaa092.

Serafin MB, Bottega A, Foletto VS, da Rosa TF, Hörner A, and Hörner R. 2020. Drug repositioning an alternative for the treatment of coronavirus COVID-19. *International Journal of Antimicrobial Agents*:105969. DOI 10.1016/j.ijantimicag.2020.105969.

Sifuentes-Rodriguez E, and Palacios-Reyes D. 2020. COVID-19: The outbreak caused by a new coronavirus. *Boletin Medico Del Hospital Infantil De Mexico* 77:47-53. DOI 10.24875/bmhim.20000039.

Siordia JA. 2020. Epidemiology and Clinical Features of COVID-19: A Review of Current Literature. *Journal of Clinical Virology*:104357. DOI 10.1016/j.jcv.2020.104357.

Stern D, López-Olmedo N, Pérez-Ferrer C, González-Morales R, Canto-Osorio F, and Barrientos-Gutiérrez T. 2020. Revisión rápida del uso de cubrebocas quirúrgicos en
806 ámbito comunitario e infecciones respiratorias agudas. *Salud Pública de México*. DOI
807 10.21149/11379.
808 Torales J, Higgins M, Castaldelli-Maia JM, and Ventriglio A. 2020. The outbreak of COVID-19
809 coronavirus and its impact on global mental health. *International Journal of Social
810 Psychiatry*:20764020915212-20764020915212. DOI 10.1177/0020764020915212.
811 Torres I, and Sacoto F. 2020. Localising an asset-based COVID-19 response in Ecuador. *The
812 Lancet*. DOI 10.1016/S0140-6736(20)30851-5.
813 Trujillo A. 2020. Response to Wen and Li. Anesthesia Procedure of Emergency Operation for
814 Patients with Suspected or Confirmed COVID-19 (DOI: 10.1089/sur.2020.040). *Surg
815 infect.*(Larchmt). DOI 10.1089/sur.2020.088.
816 van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, Tamin
817 A, Harcourt JL, Thornburg NJ, Gerber SI, Lloyd-Smith JO, de Wit E, and Munster VJ.
818 2020. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1.
819 *New England Journal of Medicine*. DOI 10.1056/NEJMc2004973.
820 Vega-Vega O, Arvizu-Hernández M, Domínguez-Cherit JG, Sierra-Madero J, and Correa-Rotter
821 R. 2020. Prevención y control de la infección por coronavirus SARS-CoV-2 (Covid-19)
822 en unidades de hemodiálisis. *Salud Pública de México*. DOI 10.21149/11330.
823 Wu D, Wu T, Liu Q, and Yang Z. 2020. The SARS-CoV-2 outbreak: What we know.
824 *International Journal of Infectious Diseases* 94:44-48. DOI 10.1016/j.ijid.2020.03.004.
825 Xu B, Gutierrez B, Mekaru S, Sewalk K, Goodwin L, Loskill A, Cohn EL, Hswen Y, Hill SC,
826 Cobo MM, Zarebski AE, Li S, Wu CH, Hulland E, Morgan JD, Wang L, O’Brien K,
827 Scarpino SV, Brownstein JS, Pybus OG, Pigott DM, and Kraemer MUG. 2020.
Epidemiological data from the COVID-19 outbreak, real-time case information. *Scientific Data* 7. DOI 10.1038/s41597-020-0448-0.

Zambrano LI, Fuentes-Barahona IC, Bejarano-Torres DA, Bustillo C, Gonzales G, Vallecillo-Chinchilla G, Sanchez-Martínez FE, Valle-Reconco JA, Sierra M, Bonilla-Aldana DK, Cardona-Ospina JA, and Rodríguez-Morales AJ. 2020. A pregnant woman with COVID-19 in Central America. *Travel Medicine and Infectious Disease*;101639. DOI 10.1016/j.tmaid.2020.101639.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, and Tan W. 2020. A novel coronavirus from patients with pneumonia in China, 2019. *New England Journal of Medicine* 382:727-733. DOI 10.1056/NEJMoA2001017.
Figure 1

PRISMA Flow diagram of selection process of COVID-19 or SAR-CoV-2 publications containing researchers with Latin American affiliation.

Identification stage was performed on April 10, 2020.
PRISMA 2009 Flow Diagram

Records identified through database searching:
Scopus (35), Web of Science (19), PubMed (98), Wiley (19),
ScienceDirect (60), Sage (1), LILACS (43), and Scielo (26)
(n=301)

Records after duplicates removed
(n=161)

Records excluded
Articles without Latin American affiliation
after manual revision.
(1 from New Mexico and 7 from Pennsylvania)
(n=8)

Records screened
(n=161)

Full-text articles assessed for eligibility
(n=153)

Studies included in qualitative synthesis
(n=153)

Manuscript to be reviewed

PeerJ reviewing PDF | (2020:04:48112:2:0:NEW 17 May 2020)
Figure 2

Classification of publications by category

Other publications refer to: Consensus statement, Contribution, and Technical note.
Figure 3

Classification of publications according to the national affiliation.

Several authors from the same country in a publication were counted as one contribution to the country. Publications with authors from different countries were counted as one for each country. Latin American countries not shown had no publications until April 10, 2020.
Medical considerations refer to surgery recommendations, diagnosis, comorbidities, medical guidelines, dentistry considerations, among others. The general aspects include zoonotic links, spreading, origin, disease, surveillance, among others. Bioinformatics refers to molecular and phylogenetic analyses, molecular simulations, genetic annotations, among others.
Figure 5

Phylogenetic location of genome sequences of some strains isolated in Latin America in the SARS-CoV-2 phylogenetic tree.

The phylogenetic tree was generated and adapted from the GISAID database (Hadfield et al., 2018; Sagulenko et al., 2018). The tree was retrieved on April 20, 2020.
Table 1 (on next page)

Summary of the COVID-19 outbreak affectation in the Latin American countries.

Total cases and total deaths are reported until April 20, 2020 (Johns Hopkins University 2020).
| Country             | First case | Cases  | Deaths |
|---------------------|------------|--------|--------|
| Argentina           | Mar 3      | 2941   | 136    |
| Bolivia             | Mar 10     | 564    | 33     |
| Brazil              | Feb 25     | 40581  | 2845   |
| Chile               | Mar 3      | 10507  | 139    |
| Colombia            | Mar 6      | 3963   | 189    |
| Costa Rica          | Mar 6      | 662    | 6      |
| Cuba                | Mar 11     | 1087   | 36     |
| Dominican Rep.      | Mar 1      | 4964   | 235    |
| Ecuador             | Feb 14     | 10128  | 507    |
| El Salvador         | Mar 18     | 218    | 7      |
| Guatemala           | Mar 13     | 289    | 7      |
| Haiti               | Mar 2      | 47     | 3      |
| Honduras            | Mar 11     | 477    | 46     |
| Mexico              | Feb 27     | 8261   | 686    |
| Nicaragua           | Mar 18     | 10     | 2      |
| Panama              | Mar 8      | 4467   | 126    |
| Paraguay            | Mar 7      | 208    | 8      |
| Peru                | Mar 6      | 16325  | 445    |
| Uruguay             | Mar 13     | 528    | 10     |
| Venezuela           | Mar 13     | 256    | 9      |
| **Total**           |            | 106483 | 5475   |
Table 2 (on next page)

Summary of genome sequences of SARS-CoV-2 strains isolated in Latin America and collected in GISAID database.

Information updated on April 20, 2020 (Hadfield et al. 2018; Sagulenko et al. 2018).
| Country   | Submitting lab                                                                 | Location                                      | Total |
|-----------|--------------------------------------------------------------------------------|-----------------------------------------------|-------|
| Argentina | Instituto Nacional Enfermedades Infecciosas C.G. Malbran                         | Argentina                                     | 3     |
| Brazil    | Bioinformatics Laboratory - LNCC                                                 | Goiás                                         | 1     |
|           |                                                                                | Minas Gerais                                  | 5     |
|           |                                                                                | Rio de Janeiro                                | 7     |
|           |                                                                                | Rio Grande do Sul                             | 1     |
|           |                                                                                | São Paulo                                     | 4     |
|           | Instituto Adolfo Lutz, Interdisciplinary Procedures Center, Strategic Laboratory | Brasília                                       | 1     |
|           |                                                                                | São Paulo                                     | 2     |
|           |                                                                                | São Paulo                                     | 11    |
|           | Instituto Oswaldo Cruz FIOCRUZ - Laboratory of Respiratory Viruses and Measles (LVRS) | Maceio                                        | 1     |
|           |                                                                                | Feira de Santana                               | 2     |
|           |                                                                                | Brasília                                      | 5     |
|           |                                                                                | Vila Velha                                    | 1     |
|           |                                                                                | Niterói                                       | 1     |
|           |                                                                                | Rio de Janeiro                                | 6     |
|           |                                                                                | Florianópolis                                 | 1     |
|           |                                                                                | Joinville                                     | 1     |
|           | Laboratorio de Ecologia de Doencas Transmissiveis na Amazonia, Instituto Leonidas e Maria Deane - Fiocruz Amazonia | Manaus                                        | 1     |
|           | Laboratory of Virology                                                         | Brasília                                      | 1     |
| Chile     | Instituto de Salud Publica de Chile                                            | Santiago                                      | 2     |
|           |                                                                                | Talca                                         | 2     |
|           | MSHS Pathogen Surveillance Program                                             | Santiago                                      | 3     |
| Colombia  | Instituto Nacional de Salud Universidad Cooperativa de Colombia Instituto Alexander von Humboldt Imperial College-London London School of Hygiene & Tropical Medicine | Antioquia                                     | 1     |
|           |                                                                                | Bogota                                        | 1     |
| Ecuador   | Institute of Microbiology, Universidad San Francisco de Quito                   | Pichincha                                     | 3     |
|           |                                                                                | Quito                                         | 1     |
| Mexico    | Instituto de Diagnostico y Referencia Epidemiologicos (INDRE)                  | Chiapas                                       | 1     |
|           |                                                                                | Estado de Mexico                              | 1     |
|           |                                                                                | Mexico City                                   | 2     |
|           |                                                                                | Puebla                                        | 1     |
|           |                                                                                | Querétaro                                     | 1     |
|           | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran              | Mexico City                                   | 5     |
|           | Instituto Nacional de Enfermedades Respiratorias                              | Mexico City                                   | 5     |
|           | Laboratorio Central de Epidemiologia-DLVIE / Laboratorio de Secuenciación-Centro de Instrumentos. Instituto Mexicano del Seguro Social | Chihuahua                                     | 1     |
| Nepal*    | The University of Hong Kong                                                    | Kathmandu                                     | 1     |
| Panama    | Gorgas Memorial Institute for Health Studies                                  | Panama City                                   | 1     |
| Peru      | Laboratorio de Referencia Nacional de Biotecnologia y Biologia Molecular. Instituto Nacional de Salud Peru | Lima                                          | 2     |
| Uruguay   | Microbial Genomics Laboratory, Institut Pasteur Montevideo                      | Montevideo                                    | 9     |
|           |                                                                                |                                              | 98    |

1 Nepal was included due to researchers with Colombian and Honduran affiliations contributed in its genome sequencing (Sah et al. 2020).